Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

MLA

Salles, Gilles A., et al. “Obinutuzumab (GA101) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase II GAUGUIN Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 31, no. 23, Aug. 2013, pp. 2920–26. EBSCOhost, https://doi.org/10.1200/JCO.2012.46.9718.

APA

Salles, G. A., Morschhauser, F., Solal-Céligny, P., Thieblemont, C., Lamy, T., Tilly, H., Gyan, E., Lei, G., Wenger, M., Wassner-Fritsch, E., & Cartron, G. (2013). Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(23), 2920–2926. https://doi.org/10.1200/JCO.2012.46.9718

Chicago

Salles, Gilles A, Franck Morschhauser, Philippe Solal-Céligny, Catherine Thieblemont, Thierry Lamy, Hervé Tilly, Emmanuel Gyan, et al. 2013. “Obinutuzumab (GA101) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase II GAUGUIN Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31 (23): 2920–26. doi:10.1200/JCO.2012.46.9718.